Extended Data Table 3 Change in lipid/lipoprotein parameters from baseline to week 24

From: Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

  1. aLDL-C was determined by ultracentrifugation. Apo, apolipoprotein; DB, double blind; HDL-C, high-density lipoprotein choleserol; IV, intravenous; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); Q1, first quartile; Q3, third quartile; Q4W, every 4 weeks; SD, standard deviation.
Back to article page